BR112015005997A8 - Composto - Google Patents
CompostoInfo
- Publication number
- BR112015005997A8 BR112015005997A8 BR112015005997A BR112015005997A BR112015005997A8 BR 112015005997 A8 BR112015005997 A8 BR 112015005997A8 BR 112015005997 A BR112015005997 A BR 112015005997A BR 112015005997 A BR112015005997 A BR 112015005997A BR 112015005997 A8 BR112015005997 A8 BR 112015005997A8
- Authority
- BR
- Brazil
- Prior art keywords
- hiv
- aids
- oxo
- methyl
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 6
- 208000030507 AIDS Diseases 0.000 abstract 3
- 206010001513 AIDS related complex Diseases 0.000 abstract 2
- 102100034343 Integrase Human genes 0.000 abstract 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 abstract 2
- 230000001506 immunosuppresive effect Effects 0.000 abstract 2
- ZIAOVIPSKUPPQW-UHFFFAOYSA-N 3-chloro-5-[1-[(4-methyl-5-oxo-1h-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)pyridin-3-yl]oxybenzonitrile Chemical compound N1C(=O)N(C)C(CN2C(C(OC=3C=C(C=C(Cl)C=3)C#N)=C(C=C2)C(F)(F)F)=O)=N1 ZIAOVIPSKUPPQW-UHFFFAOYSA-N 0.000 abstract 1
- 208000029483 Acquired immunodeficiency Diseases 0.000 abstract 1
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 208000001388 Opportunistic Infections Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 241001430294 unidentified retrovirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705780P | 2012-09-26 | 2012-09-26 | |
| PCT/US2013/060787 WO2014052171A1 (en) | 2012-09-26 | 2013-09-20 | Crystalline form of a reverse transcriptase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015005997A2 BR112015005997A2 (pt) | 2017-07-04 |
| BR112015005997A8 true BR112015005997A8 (pt) | 2023-04-11 |
Family
ID=50388877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015005997A BR112015005997A8 (pt) | 2012-09-26 | 2013-09-20 | Composto |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9150539B2 (https=) |
| EP (1) | EP2900240B1 (https=) |
| JP (2) | JP6387349B2 (https=) |
| CN (2) | CN104684557A (https=) |
| BR (1) | BR112015005997A8 (https=) |
| CA (1) | CA2882947A1 (https=) |
| ES (1) | ES2773105T3 (https=) |
| MX (1) | MX362517B (https=) |
| WO (1) | WO2014052171A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2930585A1 (en) | 2013-12-04 | 2015-06-11 | Merck Sharp & Dohme Corp. | Process for making reverse transcriptase inhibitors |
| US11077050B2 (en) | 2017-03-24 | 2021-08-03 | Merck Sharp & Dohme Corp. | Formulation for parenteral administration |
| IL294108A (en) * | 2019-12-20 | 2022-08-01 | Epizyme Inc | Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7309700B2 (en) * | 2004-04-02 | 2007-12-18 | Boehringer Ingelheim International Gmbh | Crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2′,3′-e] [1,4]diazepin-6-one |
| WO2006010545A1 (en) * | 2004-07-27 | 2006-02-02 | F. Hoffmann-La Roche Ag | Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors |
| BRPI0811988B1 (pt) * | 2007-05-30 | 2021-05-25 | F. Hoffmann-La Roche Ag | Composto intermediário e processo para preparação de triazolonas |
| CN101952274A (zh) * | 2007-11-20 | 2011-01-19 | 默沙东公司 | 非核苷逆转录酶抑制剂 |
| SI2924034T1 (sl) * | 2010-03-30 | 2017-05-31 | Merck Canada Inc. | Farmacevtski sestavek, ki obsega nenukleozidni inhibitor reverzne transkriptaze |
| EP2558093A4 (en) * | 2010-04-08 | 2013-10-02 | Merck Sharp & Dohme | PRODRUGS OF HIV INVERTER TRANSCRIPTASE INHIBITOR |
-
2013
- 2013-09-20 CA CA2882947A patent/CA2882947A1/en not_active Abandoned
- 2013-09-20 US US14/430,657 patent/US9150539B2/en active Active
- 2013-09-20 ES ES13840379T patent/ES2773105T3/es active Active
- 2013-09-20 EP EP13840379.5A patent/EP2900240B1/en active Active
- 2013-09-20 MX MX2015003767A patent/MX362517B/es active IP Right Grant
- 2013-09-20 CN CN201380050220.9A patent/CN104684557A/zh active Pending
- 2013-09-20 JP JP2015534567A patent/JP6387349B2/ja active Active
- 2013-09-20 WO PCT/US2013/060787 patent/WO2014052171A1/en not_active Ceased
- 2013-09-20 CN CN201811295039.5A patent/CN109384765A/zh active Pending
- 2013-09-20 BR BR112015005997A patent/BR112015005997A8/pt not_active Application Discontinuation
-
2017
- 2017-09-06 JP JP2017170788A patent/JP2018024683A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US9150539B2 (en) | 2015-10-06 |
| MX362517B (es) | 2019-01-21 |
| JP2015531372A (ja) | 2015-11-02 |
| ES2773105T3 (es) | 2020-07-09 |
| CN109384765A (zh) | 2019-02-26 |
| US20150232447A1 (en) | 2015-08-20 |
| JP2018024683A (ja) | 2018-02-15 |
| WO2014052171A1 (en) | 2014-04-03 |
| EP2900240B1 (en) | 2020-01-08 |
| EP2900240A1 (en) | 2015-08-05 |
| EP2900240A4 (en) | 2016-07-13 |
| BR112015005997A2 (pt) | 2017-07-04 |
| JP6387349B2 (ja) | 2018-09-05 |
| CA2882947A1 (en) | 2014-04-03 |
| MX2015003767A (es) | 2015-07-14 |
| CN104684557A (zh) | 2015-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519402405B1 (ar) | مركبات مثبط فيروس نقص المناعة البشري | |
| CY1124855T1 (el) | 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες | |
| CU24340B1 (es) | Derivados de acetamidas fluoradas para el tratamiento del vih | |
| MX369307B (es) | Compuestos terapeuticos utiles para tratamiento profilactico o terapeutico de infeccion por virus de inmunodeficiencia humana. | |
| CL2015000880A1 (es) | Compuestos heterociclicos derivados de 4-pirimidinona, inhibidores de la transcriptasa inversa del vih; composicion farmaceutica; uso en la profilaxis o el tratamiento de infeccion por vih o para la profilaxis, tratamiento o retraso de la aparicion del sida en un sujeto. | |
| CY1118774T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης | |
| CL2012002080A1 (es) | Una combinación que comprende (4r,12as)-n-[2,4-fluoro-fenil)-metil]-3,4,6,8,12,12a-hexahidro-7-hidroxi-4-metil-6,8-dioxo-2h-pirido-{1',2':4,5]-pirazino-[2,1-b][1,3]-oxazin-9-carboxamida (gsk1349572) y uno o mas del grupo: abacavir, efavirenz y lopinavir, adicionalmente puede contener lamivudina, útil para el tratamiento del vih. | |
| PH12015501156A1 (en) | Pharmaceutical compositions | |
| MX358099B (es) | Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos. | |
| EA200901490A1 (ru) | Химические соединения | |
| MA39995B1 (fr) | Composés destinés à traiter l'amyotrophie spinale | |
| CO2021012579A2 (es) | Compuestos útiles en la terapia del vih | |
| CL2015001538A1 (es) | Compuestos derivados de piridin-2-amidas, agonistas cb2; proceso de preparacion; composicion farmaceutica que los contiene; su uso para el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, glaucoma, diabetes mellitus, entre otras. | |
| MA46101B1 (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
| ECSP109897A (es) | Composiciones terapeuticas y usos de las mismas | |
| BR112015005997A8 (pt) | Composto | |
| EA202191711A1 (ru) | Производные пиримидона в качестве селективных цитотоксических агентов против вич-инфицированных клеток | |
| MX2017003928A (es) | Composiciones farmaceuticas de accion prolongada. | |
| AR120655A1 (es) | Anticuerpos ampliamente neutralizantes contra vih | |
| BR112017002675A2 (pt) | métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila | |
| BR112014003989A2 (pt) | composto, composições e métodos para inibir a replicação do hiv-1 em paciente, para tratar pacientes infectados com hiv/aids e para profilaxia de pré-exposição para tratar paciente e para prevenir a transmissão de pessoa infectada para pessoa não infectada | |
| WO2014201426A3 (en) | Triazol-1-ol analogs anti-retroviral latency drugs | |
| JP2013508349A5 (https=) | ||
| CU24569B1 (es) | Composición farmacéutica como antagonista del receptor de mineralocorticoides | |
| PE20130529A1 (es) | Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: MERCK SHARP AND DOHME LLC (US) |